Every material Form 8-K TELA Bio, Inc. has filed with the SEC since September 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TELA Bio, Inc. received a letter from The Nasdaq Stock Market on October 5, 2026, stating that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market, and the matter is now closed. The company's common stock continues to trade on the Nasdaq Global Market under the symbol TELA, so shareholders face no change in listing status.
Nasdaq letter received October 5, 2026 confirms compliance with the minimum bid price requirement under Listing Rule 5450(a)(1)
Nasdaq matter is closed
Common stock continues to trade on the Nasdaq Global Market under the symbol TELA
TELA Bio said the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. The company said Liora is the first implant fully developed in its ISO 8 certified cleanroom in Malvern, PA, and that it expands TELA Bio's footprint in the soft tissue reconstruction market. The filing does not include financial figures or sales expectations for the product.
FDA granted 510(k) clearance for the Liora Monofilament Scaffold, announced October 5, 2026
Liora is described as a fully resorbable surgical mesh device for soft tissue reinforcement
Liora is the first implant fully developed in the company's ISO 8 certified cleanroom in Malvern, PA
More details are expected on the third quarter earnings call, expected in early November
TELA Bio entered into a Limited Consent to its credit agreement on September 28, 2026, with Perceptive Credit Holdings V, LP, as administrative agent, and the Required Lenders. The consent means the minimum Revenue covenant in Section 10.02 of the credit agreement will not be tested for the quarters ending on or about September 30, 2026 and December 31, 2026. The filing does not state the reason for the consent.
Limited Consent dated September 28, 2026, amending the credit agreement dated November 13, 2025
Minimum Revenue covenant in Section 10.02 not tested for quarters ending on or about September 30, 2026 and December 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TELA Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →